Highlights

  • Telix Pharmaceuticals reported June quarter revenue of US$247 million, taking first-half FY26 revenue to approximately US$477 million.
  • FY26 revenue and other income guidance was increased to more than US$1 billion, including a US$40 million Regeneron payment.
  • The company commenced dosing in the Phase 3 LUTEON study for relapsed clear cell kidney cancer.
  • Research and development guidance increased to US$230 million to US$270 million for FY26.
  • Regulatory progress continues across multiple programs, including Pixclara and Zircaix.

Telix Pharmaceuticals Limited (ASX: TLX) continues to expand its radiopharmaceutical business as commercial revenue growth is accompanied by ongoing investment in clinical development programs.

The company develops radiopharmaceutical products that combine imaging and therapeutic applications in cancer care. Its current commercial activities are centred around prostate cancer imaging products, while its pipeline includes multiple therapeutic and diagnostic programs across different cancer indications.

In July 2026, Telix reported continued revenue growth and provided an updated outlook for FY26. The company also progressed clinical activities, including the first patient dosing in the Phase 3 LUTEON study.

Revenue Growth and FY26 Outlook Update

For the three months ended 30 June 2026, Telix reported group revenue of US$247 million, representing growth of 7% compared with the previous quarter and 21% year-on-year.

The Precision Medicine division contributed US$202 million during the quarter, increasing 30%, while Manufacturing Solutions generated US$45 million of third-party revenue.

The June quarter result brought first-half FY26 revenue to approximately US$477 million.

The company updated its FY26 outlook, stating that revenue and other income is expected to exceed US$1 billion. This includes a US$40 million non-refundable payment from Regeneron. The underlying revenue guidance remained within the previously stated range of US$950 million to US$970 million.

Alongside revenue expectations, Telix increased its FY26 research and development guidance to US$230 million to US$270 million from the previous range of US$200 million to US$240 million.

Clinical Pipeline Progress Through LUTEON Study

Telix continued to progress its therapeutic pipeline during July 2026 with the first patient dosed in the Phase 3 LUTEON study.

The study evaluates TLX250-Tx in patients with relapsed or recurrent clear cell renal cell carcinoma, a form of kidney cancer. The treatment targets carbonic anhydrase IX, a protein associated with clear cell tumours.

The company also reported progress in its ProstACT Global program. Following discussions with the US Food and Drug Administration, Telix confirmed that safety data from the 36-patient lead-in supported progression to the second part of the Phase 3 study.

The ProstACT Global study is evaluating TLX591-Tx for prostate cancer treatment.

Commercial Products and Regulatory Developments

Telix operates across three main areas: Precision Medicine, Therapeutics and Manufacturing Solutions.

Precision Medicine currently generates most of the company’s commercial revenue through products including Illuccix and Gozellix, which are used in prostate cancer imaging.

The company continues to progress regulatory activities for additional products. Pixclara’s resubmitted application has been accepted by the FDA, with a decision goal date of 11 September 2026.

Zircaix remains under regulatory review. Telix has stated that discussions with regulators have focused on outstanding manufacturing comparability matters between clinical and commercial-scale product.

The company is also developing additional therapeutic and imaging combinations through its pipeline.

Financial Position and Debt Management

For the year ended 31 December 2025, Telix reported revenue of US$803.8 million, representing growth of 56%.

The company recorded gross profit of US$426.4 million and adjusted EBITDA of US$39.5 million. Loss before tax was US$5.3 million, including US$26.7 million of non-cash finance costs related to convertible bonds.

Research and development expenditure totalled US$157.1 million during FY25.

At the end of 2025, Telix held cash of US$141.9 million. During 2026, the company completed a refinancing process involving US$600 million of new convertible bonds due in 2031 and repurchased its previous 2029 notes.

The company’s June 2026 half-year results are expected to provide an updated cash position following these activities.

Key Factors Influencing Future Progress

Telix’s future performance will depend on continued commercial growth, regulatory outcomes and progress across clinical programs.

Important upcoming developments include the FDA decision timeline for Pixclara, further progress on Zircaix, updates from clinical trials and financial results for the first half of 2026.

The company’s ability to manage research investment while expanding commercial activities will remain an important area of focus.

Risks and Challenges

Telix continues to operate across a highly regulated healthcare environment, with regulatory approval timelines influencing product expansion.

Clinical development programs also involve uncertainty, as trial outcomes and regulatory decisions remain outside the company’s control.

The company is investing significantly in research and development while managing debt obligations associated with its financing arrangements.

Conclusion

Telix Pharmaceuticals has continued to expand its commercial operations while advancing its radiopharmaceutical pipeline. Revenue growth during the June quarter and updated FY26 revenue and other income expectations reflect continued business development.

At the same time, the company remains focused on clinical trials, regulatory submissions and product expansion activities. Future updates on regulatory decisions, clinical progress and financial performance will provide further insight into the company’s development path.